TARGOCID 200MG POWDER FOR SOLUTION FOR INJECTION/INFUSION FOR INTRAVENOUS, INTRAMUSCULAR USE

Product Information

Registration Status: Active

TARGOCID 200MG POWDER FOR SOLUTION FOR INJECTION/INFUSION is approved to be sold in Singapore with effective from 1990-09-29. It is marketed by SANOFI-AVENTIS SINGAPORE PTE LTD, with the registration number of SIN05117P.

This product contains Teicoplanin 200mg/vial in the form of INJECTION, POWDER, FOR SOLUTION. It is approved for INTRAVENOUS, INTRAMUSCULAR use.

This product is manufactured by Gruppo Lepetit S.r.l. in ITALY.

It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.

Description

Teicoplanin is a glycopeptide antibiotic. It is a mixture of several compounds, five major (named teicoplanin A2-1 through A2-5) and four minor (named teicoplanin RS-1 through RS-4). All teicoplanins share a same glycopeptide core, termed teicoplanin A3-1, a fused ring structure to which two carbohydrates (mannose and N-acetylglucosamine) are attached. The major and minor components also contain a third carbohydrate moiety, β-D-glucosamine, and differ only by the length and conformation of a side chain attached to it.

Indication

For the treatment of bacterial infections caused by susceptible microorganisms.

Mechanism of Action

Teicoplanin inhibits peptidoglycan polymerization, resulting in inhibition of bacterial cell wall synthesis and cell death.

Pharmacokinetics

Absorption: Teicoplanin is poorly absorbed after oral administration but is 90% bioavailable when administered intramuscularly.
Distribution
Metabolism: Two metabolites (metabolites 1 and 2; 2 to 3% of total teicoplanin) have been isolated after intravenous administration of radiolabeled teicoplanin. After purification, their structures were found to be new teicoplanin-like molecules, bearing 8-hydroxydecanoic and 9-hydroxydecanoic acyl moieties. This metabolic transformation is likely due to hydroxylation in the omega-2 and omega-1 positions for metabolites 1 and 2, respectively, of the C-10 linear side chain of component A2-3. This might explain the low extent of metabolism of teicoplanin if we consider that only component A2-3 has a linear chain that is susceptible to such oxidation.
Elimination

Active Ingredient/Synonyms

Source of information: Drugbank (External Link). Last updated on: 3^rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.